Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Kodiak Sciences stock

KOD
US50015M1099
A2N6P0

Price

4.09
Today +/-
-0.26
Today %
-6.80 %
P

Kodiak Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kodiak Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kodiak Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kodiak Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kodiak Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kodiak Sciences Stock Price History

DateKodiak Sciences Price
11/5/20244.09 undefined
11/5/20244.38 undefined
11/4/20243.90 undefined
11/1/20243.84 undefined
10/31/20243.80 undefined
10/30/20243.95 undefined
10/29/20243.93 undefined
10/28/20243.73 undefined
10/25/20243.74 undefined
10/24/20243.43 undefined
10/23/20243.54 undefined
10/22/20243.65 undefined
10/21/20243.67 undefined
10/18/20243.62 undefined
10/17/20243.30 undefined
10/16/20243.00 undefined
10/15/20242.88 undefined
10/14/20242.89 undefined
10/11/20242.84 undefined
10/10/20242.69 undefined
10/9/20242.62 undefined
10/8/20242.65 undefined

Kodiak Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kodiak Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kodiak Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kodiak Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kodiak Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kodiak Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kodiak Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kodiak Sciences’s growth potential.

Kodiak Sciences Revenue, EBIT and net profit per share

DateKodiak Sciences RevenueKodiak Sciences EBITKodiak Sciences Net Income
2030e1.04 B undefined444.75 M undefined333.43 M undefined
2029e592.34 M undefined299.3 M undefined220.51 M undefined
2028e397.97 M undefined111.82 M undefined90.86 M undefined
2027e206.77 M undefined-50.46 M undefined-39.32 M undefined
2026e0 undefined-301.88 M undefined-192.53 M undefined
2025e0 undefined-223.99 M undefined-202.01 M undefined
2024e0 undefined-197.88 M undefined-187.13 M undefined
20230 undefined-277.32 M undefined-260.49 M undefined
20220 undefined-341.38 M undefined-333.82 M undefined
20210 undefined-267.05 M undefined-266.99 M undefined
20200 undefined-136.01 M undefined-133.1 M undefined
20190 undefined-49.19 M undefined-47.37 M undefined
20180 undefined-26.37 M undefined-41.44 M undefined
20170 undefined-25.52 M undefined-27.94 M undefined
20160 undefined-17.15 M undefined-17.13 M undefined

Kodiak Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000000000.210.40.591.04
------------92.7249.1275.51
---------------
000000000000000
-17-25-26-49-136-267-341-277-197-223-301-50111299444
------------24.2727.9650.5142.73
-17-27-41-47-133-266-333-260-187-202-192-3990220333
-58.8251.8514.63182.98100.0025.19-21.92-28.088.02-4.95-79.69-330.77144.4451.36
35.3735.3736.9137.8545.7451.7952.2552.410000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Kodiak Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kodiak Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
20162017201820192020202120222023
               
9.61.488.3336.5969731.5478.9285.51
00000000
00000000
00000000
0.60.22.22.733.37.13.8
10.21.690.5339.2972734.8486289.31
1.81.51.12.878.8108.1115.8175.02
00011.70000
00000000
00000000
00000000
0.10.10.65.216.561.364.915.04
1.91.61.719.795.3169.4180.7190.06
0.0100.090.361.070.90.670.48
               
5050000000.01
000.20.51.151.221.331.42
-41.4-69.3-110.8-158.1-291.2-558.2-892-1,152.53
00001000-1,3000
00000000
8.9-18.786.8345.4860.8663.3436.2265.78
1.13.41.12.68.612.49.113.61
1.35.63.89.122.852.343.428.12
100100000000
00000000
100100000000
2.69.24.911.731.464.752.541.73
0.112.3000000
00000000
0.60.50.51.8175.2176.2178171.86
0.712.80.51.8175.2176.2178171.86
3.3225.413.5206.6240.9230.5213.59
0.0100.090.361.070.90.670.48
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kodiak Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kodiak Sciences's financial health and stability.

Assets

Kodiak Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kodiak Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kodiak Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kodiak Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2016201720182019202020212022
-17-27-41-47-133-266-333
0000013
0000000
07-61141411
02201265130217
0000000
0000000
-16-17-29-39-83-182-206
0000-7-63-47
000-137104-38-336
000-13611124-289
0000000
09320000
008329961881
0911629971781
00009900
0000000
-16-886123738-212-541
-16.82-17.87-29.61-39.59-90.43-245.57-253.82
0000000

Kodiak Sciences stock margins

The Kodiak Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kodiak Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kodiak Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kodiak Sciences's sales revenue. A higher gross margin percentage indicates that the Kodiak Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kodiak Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kodiak Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kodiak Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kodiak Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kodiak Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kodiak Sciences Margin History

Kodiak Sciences Gross marginKodiak Sciences Profit marginKodiak Sciences EBIT marginKodiak Sciences Profit margin
2030e0 %42.81 %32.09 %
2029e0 %50.53 %37.23 %
2028e0 %28.1 %22.83 %
2027e0 %-24.4 %-19.02 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

Kodiak Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Kodiak Sciences earnings per share therefore indicates how much revenue Kodiak Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kodiak Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kodiak Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kodiak Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kodiak Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kodiak Sciences Revenue, EBIT and net profit per share

DateKodiak Sciences Sales per ShareKodiak Sciences EBIT per shareKodiak Sciences Earnings per Share
2030e19.75 undefined0 undefined6.34 undefined
2029e11.26 undefined0 undefined4.19 undefined
2028e7.56 undefined0 undefined1.73 undefined
2027e3.93 undefined0 undefined-0.75 undefined
2026e0 undefined0 undefined-3.66 undefined
2025e0 undefined0 undefined-3.84 undefined
2024e0 undefined0 undefined-3.56 undefined
20230 undefined-5.29 undefined-4.97 undefined
20220 undefined-6.53 undefined-6.39 undefined
20210 undefined-5.16 undefined-5.16 undefined
20200 undefined-2.97 undefined-2.91 undefined
20190 undefined-1.3 undefined-1.25 undefined
20180 undefined-0.71 undefined-1.12 undefined
20170 undefined-0.72 undefined-0.79 undefined
20160 undefined-0.48 undefined-0.48 undefined

Kodiak Sciences business model

Kodiak Sciences Inc. is a biotechnology company focused on developing new treatment options for eye diseases. It was founded in 2009 by Dr. Victor Perlroth and Dr. Charles Semba and is headquartered in Palo Alto, California. Kodiak's main business is the development of antibody-based medications that aim to effectively treat eye diseases and achieve better outcomes than traditional treatment methods. The company collaborates closely with universities and research institutions, particularly in the field of clinical studies, and participates in various research projects. One of Kodiak's key areas is the development of medications for retinal diseases, which can cause significant vision impairments and blindness. The company focuses on targeted inhibition of VEGF, a protein involved in the formation of blood vessels, which, when overactive, can lead to damage to the retina. Kodiak's medications aim to slow down or stop the growth of blood vessels by specifically inhibiting VEGF. Another important area of focus for Kodiak is the development of medications for glaucoma, a condition characterized by increased pressure inside the eye, leading to damage to retinal nerve fibers and cells. The company develops medications to lower intraocular pressure and prevent damage. Kodiak also develops medications for treating eye inflammation and infections, as well as disorders of the tear duct system. Overall, Kodiak is a promising biotechnology company specializing in the development of innovative medications for eye diseases. The targeted inhibition of VEGF and lowering of intraocular pressure are central to its business model. Collaboration with other companies and research institutions allows Kodiak to leverage a wide range of expertise and develop even more effective medications. Kodiak Sciences is one of the most popular companies on Eulerpool.com.

Kodiak Sciences SWOT Analysis

Strengths

Kodiak Sciences Inc has a strong foundation in the pharmaceutical industry, backed by a team of experienced professionals.

The company boasts a robust pipeline of innovative drug candidates, positioning them for future growth and increased market share.

Kodiak Sciences Inc has established strategic partnerships with leading pharmaceutical companies, enhancing their capabilities and resources.

Weaknesses

One of Kodiak Sciences Inc's weaknesses is its reliance on a limited number of drug candidates, which presents a risk in case of failure or delay in clinical trials.

The company's relative newness in the industry may result in a lack of brand recognition and market trust compared to more established competitors.

Kodiak Sciences Inc currently has a small market share and limited market presence, which can hinder their ability to compete with larger pharmaceutical companies.

Opportunities

The increasing demand for innovative pharmaceutical products presents a significant opportunity for Kodiak Sciences Inc to expand its market reach.

Advancements in technology and regulatory support for research and development create favorable conditions for Kodiak Sciences Inc to develop new drugs.

Emerging markets offer untapped potential for the company to establish a strong presence and capture additional market share.

Threats

Intense competition within the pharmaceutical industry poses a threat to Kodiak Sciences Inc's market position and profitability.

The regulatory landscape and potential changes in healthcare policies could impact the company's ability to bring drugs to market or affect profitability.

Failure to effectively protect intellectual property may expose Kodiak Sciences Inc to the risk of competitors imitating or infringing on their innovations.

Kodiak Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kodiak Sciences historical P/E ratio, EBIT multiple, and P/S ratio

Kodiak Sciences shares outstanding

The number of shares was Kodiak Sciences in 2023 — This indicates how many shares 52.414 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kodiak Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kodiak Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kodiak Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kodiak Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Kodiak Sciences.

Kodiak Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.88 -0.86  (2.39 %)2024 Q2
3/31/2024-1.08 -0.82  (24 %)2024 Q1
12/31/2023-0.78 -1.13  (-44.67 %)2023 Q4
9/30/2023-1.22 -0.95  (22.08 %)2023 Q3
6/30/2023-1.15 -1.53  (-32.73 %)2023 Q2
3/31/2023-1.34 -1.35  (-0.8 %)2023 Q1
12/31/2022-1.54 -1.35  (12.37 %)2022 Q4
9/30/2022-1.79 -1.47  (17.71 %)2022 Q3
6/30/2022-1.77 -1.74  (1.84 %)2022 Q2
3/31/2022-1.55 -1.83  (-17.78 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Kodiak Sciences stock

Eulerpool World ESG Rating (EESG©)

29/ 100

🌱 Environment

30

👫 Social

41

🏛️ Governance

17

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Kodiak Sciences shareholders

%
Name
Stocks
Change
Date
32.90342 % Baker Bros. Advisors LP17,310,49006/30/2024
5.33111 % BlackRock Institutional Trust Company, N.A.2,804,695-26,7576/30/2024
5.12267 % Perlroth (Victor D)2,695,03804/1/2024
3.73588 % Acadian Asset Management LLC1,965,449242,5596/30/2024
3.14662 % The Vanguard Group, Inc.1,655,4399916/30/2024
2.01875 % SilverArc Capital Management, LLC1,062,062-176,7606/30/2024
1.93283 % ICONIQ Capital, LLC1,016,86406/30/2024
1.79653 % D. E. Shaw & Co., L.P.945,152-99,4986/30/2024
1.77746 % BlackRock Financial Management, Inc.935,12142,6546/30/2024
1.76772 % Newtyn Management, LLC930,000-70,0006/30/2024
1
2
3
4
5
...
10

Kodiak Sciences Executives and Management Board

Dr. Victor Perlroth(50)
Kodiak Sciences Chairman of the Board, President, Chief Executive Officer, Co-Founder
Compensation 3 M
Dr. Jason Ehrlich(47)
Kodiak Sciences Chief Medical Officer and Chief Development Officer
Compensation 1.63 M
Mr. John Borgeson(61)
Kodiak Sciences Chief Financial Officer, Executive Vice President, Secretary
Compensation 1.51 M
Mr. Robert Profusek(73)
Kodiak Sciences Lead Independent Director
Compensation 218,465
Mr. Charles Bancroft(63)
Kodiak Sciences Independent Director
Compensation 209,465
1
2

Kodiak Sciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Lonza Group Stock
Lonza Group
SupplierCustomer-0,290,84-0,160,720,690,02
AbCellera Biolog Stock
AbCellera Biolog
SupplierCustomer-0,450,710,390,850,69
1

Most common questions regarding Kodiak Sciences

What values and corporate philosophy does Kodiak Sciences represent?

Kodiak Sciences Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. With a vision to revolutionize the treatment of retinal diseases, Kodiak Sciences Inc fosters a corporate philosophy rooted in scientific rigor and patient-centricity. The company strives to develop transformative therapies addressing unmet medical needs, placing a strong emphasis on advanced research and development. By leveraging its proprietary technology platforms, Kodiak Sciences Inc aims to provide patients with effective and safe treatment options. With a focus on improving the quality of life for individuals affected by retinal diseases, Kodiak Sciences Inc remains dedicated to advancing ophthalmic healthcare.

In which countries and regions is Kodiak Sciences primarily present?

Kodiak Sciences Inc is primarily present in the United States.

What significant milestones has the company Kodiak Sciences achieved?

Kodiak Sciences Inc has achieved several significant milestones. The company successfully completed a Phase 1b clinical trial for its lead product candidate, KSI-301, demonstrating its potential as a highly effective therapy for retinal diseases. Kodiak Sciences also received Fast Track designation from the U.S. FDA for KSI-301, highlighting the potential for expedited development and review. Additionally, the company entered into a strategic collaboration with Biogen, a global biotechnology leader, to develop and commercialize potential future products based on Kodiak's novel antibody biopolymer conjugate platform. These milestones illustrate the company's progress in advancing innovative therapies and forging key partnerships in the biopharmaceutical industry.

What is the history and background of the company Kodiak Sciences?

Kodiak Sciences Inc, founded in 2009, is a clinical-stage biopharmaceutical company focused on developing novel therapies for treating retinal diseases. The company is headquartered in Palo Alto, California. Kodiak Sciences Inc specializes in discovering and developing innovative medicines using its proprietary antibody biopolymer conjugate (ABC) platform. The platform enables the creation of optimized, potent, and durable therapies for various ocular diseases. Kodiak Sciences Inc has made significant progress in developing therapies for retinal diseases, including age-related macular degeneration and diabetic eye disease. With a strong commitment to research and development, Kodiak Sciences Inc aims to improve the lives of patients suffering from vision-threatening diseases.

Who are the main competitors of Kodiak Sciences in the market?

The main competitors of Kodiak Sciences Inc in the market include companies such as Regeneron Pharmaceuticals Inc, Novartis AG, and Roche Holding AG.

In which industries is Kodiak Sciences primarily active?

Kodiak Sciences Inc is primarily active in the biotechnology industry.

What is the business model of Kodiak Sciences?

The business model of Kodiak Sciences Inc. focuses on discovering, developing, and commercializing novel therapies for retinal diseases. With a particular emphasis on diseases like age-related macular degeneration (AMD) and diabetic retinopathy, the company is dedicated to improving the lives of patients with vision-threatening conditions. Kodiak Sciences Inc. utilizes its proprietary technology platform, known as the Antibody Biopolymer Conjugate (ABC) platform, to create innovative biologics that provide extended duration treatment options. By combining cutting-edge science and a patient-centric approach, Kodiak Sciences Inc. aims to revolutionize the treatment landscape for retinal diseases.

What is the P/E ratio of Kodiak Sciences 2024?

The Kodiak Sciences P/E ratio is -1.15.

What is the P/S ratio of Kodiak Sciences 2024?

The Kodiak Sciences P/S ratio is 0.

What is the Quality Investing of Kodiak Sciences?

The Quality Investing for Kodiak Sciences is 2/10.

What is the revenue of Kodiak Sciences 2024?

The revenue cannot currently be calculated for Kodiak Sciences.

How high is the profit of Kodiak Sciences 2024?

The expected Kodiak Sciences profit is -187.13 M USD.

What is the business model of Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of various eye diseases. The company was founded in 2009 and is headquartered in Palo Alto, California.

What is the Kodiak Sciences dividend?

Kodiak Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Kodiak Sciences pay dividends?

The dividend cannot currently be calculated for Kodiak Sciences or the company does not pay out a dividend.

What is the Kodiak Sciences ISIN?

The ISIN of Kodiak Sciences is US50015M1099.

What is the Kodiak Sciences WKN?

The WKN of Kodiak Sciences is A2N6P0.

What is the Kodiak Sciences ticker?

The ticker of Kodiak Sciences is KOD.

How much dividend does Kodiak Sciences pay?

Over the past 12 months, Kodiak Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kodiak Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Kodiak Sciences?

The current dividend yield of Kodiak Sciences is .

When does Kodiak Sciences pay dividends?

Kodiak Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kodiak Sciences?

Kodiak Sciences paid dividends every year for the past 0 years.

What is the dividend of Kodiak Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kodiak Sciences located?

Kodiak Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kodiak Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kodiak Sciences from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did Kodiak Sciences pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of Kodiak Sciences in the year 2023?

In the year 2023, Kodiak Sciences distributed 0 USD as dividends.

In which currency does Kodiak Sciences pay out the dividend?

The dividends of Kodiak Sciences are distributed in USD.

All fundamentals about Kodiak Sciences

Our stock analysis for Kodiak Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kodiak Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.